ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
AstraZeneca will invest $80 million in cash and equity in Silence Therapeutics as part of a deal to develop small interfering RNA (siRNA) drugs for a variety of diseases. To start, London-based Silence will use its GalNAc-siRNA technology to inhibit liver-expressed gene targets. Mene Pangalos, AstraZeneca’s head of biopharmaceutical R&D, says the collaboration “adds an exciting new modality, siRNA, into our drug discovery toolbox.”
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter